Concord Biotech Limited (CONCORDBIO)

Loading page…

Concord Biotech Limited (CONCORDBIO) · mywealthgrid

About

Concord Biotech is a mid-sized pharmaceutical company with quarterly revenue of ₹247–326 Cr and strong operating margins averaging 34.83%. The debt-free balance sheet (D/E 0) and consistent quarterly profitability of ₹57.7–90 Cr support regular dividends, indicating stable cash generation.

Face value: ₹1

Market cap

₹14,373 Cr

P/E

52.2×

P/B

7.1×

Dividend yield

1.3%

ROE

13.6%

ROCE

17.6%

Debt / equity

OPM

34.8%

EPS (TTM)

₹26.3

Book value

₹192.8

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

High valuation multiple: PE 55.13 implies significant growth expectations; earnings disappointment or continued margin pressure could trigger material stock correction
Recent operating margin compression: OPM fell from 37.55% (Mar 2026) to 31.99% (Jun 2026) — verify whether this is temporary or indicates structural cost or demand headwinds
Negative recent performance: Stock down 11.02% over 1 year despite dividends; assess if driven by sector concerns, company-specific issues, or valuation reversion
Pharmaceutical sector exposure: Generic competition and government pricing pressure are endemic; verify if company's portfolio faces share loss or pricing power erosion

Generated analysis · source review pending

Growth drivers

Margin recovery potential: Operating margin fell from 37.55% (Mar 2026) to 31.99% (Jun 2026); resolving root causes could restore profitability on current quarterly revenue of ₹247–326 Cr
Financial capacity: Zero debt (D/E 0) allows investment in R&D, capacity expansion or M&A; verify capital allocation priorities and planned investments
Consistent cash generation: Quarterly net profit ₹57.7–90 Cr and dividends paid across 2024–2026 indicate stable operating cash flow; verify portion retained for growth versus distributed
Revenue trajectory needs clarification: Quarterly sales stable around ₹250–330 Cr with no obvious growth trend; verify if new products, markets or capacity expansion planned

Generated analysis · source review pending

766 historical price candles were omitted because the exchange source has not been verified.

₹1,374.1-2.6%1Y

Quick read

rule-based

Pros

+Strong return on equity of 25.3% (3-yr avg)
+High return on capital employed of 24.4%
+Healthy operating margin of 34.8%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 1233.2×
+Dividend payout of 69.3% of profit

Cons

−Modest revenue growth of 7.3% a year over the last 3 years

Research score

Structured signal from quality, growth, valuation and momentum.

51/100

Business quality: 75
Growth: 60

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY SMALLCAP 250 NIFTY MIDSMALLCAP 400 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	853	1,017	1,200	1,055
COGS	180	229	306	246
Gross profit	673	788	895	809
	330	353	390	439
	343	435	505	370
OPM %	40.2%	42.8%	42.1%	35.1%
Depreciation	54	54	54	74
Interest	5	3	1	0
	35	34	44	49
Profit before tax	320	413	495	345
Tax	82	104	123	85
Tax %	25.6%	25.3%	24.9%	24.8%
	240	308	372	259
PAT margin %	28.1%	30.3%	31%	24.6%
EPS (₹)	—	29.5	35.5	24.8
EPS adjusted (₹)	23	29.5	35.5	24.9
	—	29.7%	30.1%	30.5%
Annual report	—	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	10	10
Reserves	—	1,516	1,802	2,007
Minority interest	—	0	—	—
	—	6	0	0
	—	168	221	218
Total equity & liabilities	—	1,701	2,034	2,235
	593	575	794	789
CWIP	—	211	50	78
Investments	—	246	336	491
	—	668	854	877
Total assets	—	1,701	2,034	2,235

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	265	245	267
	-155	-160	-143
	-99	-99	-113
Net cash flow	12	-14	11
Free cash flow	180	133	172
CFO / Operating profit %	61.5%	48.3%	72.6%

Compounded sales growth

7 years: —
5 years: —
3 years: 7%
1 year: -12%

Compounded profit growth

7 years: —
5 years: —
3 years: 3%
1 year: -30%

Return on equity

7 years: —
5 years: —
3 years: 18%
Last year: 13%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	78.9%	77.5%	74.5%	76.7%
EBITDA margin %	40.2%	42.4%	42.2%	34.8%
EBIT margin %	33.9%	37.2%	37.7%	27.8%
PAT margin %	28.1%	30.3%	31%	24.6%
Working capital
Receivable days	—	125	159	159
Inventory days	—	331	286	485
Payable days	—	150	135	151
NWC days	—	306	310	493
Leverage
Current ratio	—	6.3	6.17	7.39
Debt to EBITDA	—	0.01	0	0
Debt to equity	—	0	0	0
Interest coverage	72	161.5	936.6	1,233.2
Asset turnover	—	0.6	0.59	0.47
Return ratios
Return on assets %	—	18.1%	18.3%	11.6%
Return on capital employed %	—	26.4%	29.1%	17.6%
Return on equity %	—	20.2%	20.5%	12.9%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%	44.08%
	7.3%	7%	6.48%	7.11%	8.1%	8.33%	9.35%	9.11%	8.03%	7.58%	7.8%	7.52%
	8.18%	8.46%	8.46%	10.4%	9.89%	9.66%	9.16%	8.87%	9.55%	9.58%	9.22%	9.36%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	40.44%	40.46%	40.98%	38.41%	37.93%	37.93%	37.41%	37.94%	38.34%	38.76%	38.9%	39.04%
No. of shareholders	—	—	—	—	—	—	—	—	82,650	81,815	82,249	83,325

Promoter holding up 0 percentage points since Sep 2023.

16 deals · 18 Aug 2023 – 31 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
31 Aug 2026	1575773 ONTARIO INC	Bulk	BSE	Sell	20,92,325	₹1,404.10	₹293.78 Cr
31 Aug 2026	DSP MUTUAL FUND	Bulk	BSE	Buy	12,88,114	₹1,404.10	₹180.86 Cr
25 Feb 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	6,16,952	₹1,217.94	₹75.14 Cr
25 Feb 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	6,16,952	₹1,218.58	₹75.18 Cr
20 Sept 2024	UBS PRINCIPAL CAPITAL ASIA LIMITED	Bulk	NSE	Sell	7,40,159	₹2,589.86	₹191.69 Cr
20 Sept 2024	THE VANGUARD GROUP INC A/C VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Bulk	NSE	Buy	6,97,936	₹2,596.08	₹181.19 Cr
20 Sept 2024	THE VANGUARD GROUP INC A/C VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNAT	Bulk	NSE	Buy	5,77,183	₹2,596.08	₹149.84 Cr
28 May 2024	1575773 ONTARIO INC	Bulk	NSE	Sell	35,48,211	₹1,361.26	₹483.00 Cr
28 May 2024	NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBAL	Bulk	NSE	Buy	6,00,000	₹1,386.95	₹83.22 Cr
25 Jan 2024	SOCIETE GENERALE	Block	BSE	Buy	1,53,421	₹1,421.70	₹21.81 Cr

1–10 of 16

1 / 2

Mr. SUDHIR JAIRAM VAIDExecutive Director-Chairperson-MD
Mr. ANKUR VAIDExecutive Director-CEO-MD
Mr. RAVI KAPOORNon-Executive - Non Independent Director
Mr. RAJIV AMBRISH AGARWALNon-Executive - Non Independent Director
Mrs. BHARTI KHANNANon-Executive - Independent Director
Mr. AMITABH GAJENDRA THAKORENon-Executive - Independent Director
Mr. JAYARAM EASWARANNon-Executive - Independent Director
Mr. ARVIND MOTILAL AGARWALNon-Executive - Independent Director
Mr. CHAKRAVARTHY SRIRAMAN MANDAYAMNon-Executive - Independent Director
Mrs. EKTA GUPTANon-Executive - Independent Director
Mr. Raviraj KariaChief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 11 fund houses

Held by these funds

4.96%

of the company's equity

All mutual funds

4.4%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

33 schemes · 11 fund houses

		Shares
Small Cap Fund	DSP Mutual Fund	26.2 L	378.85	1.75%	2.505%	+12.88 L
Healthcare Opportunities Fund	SBI Mutual Fund	9.6 L	138.83	2.4%	0.918%	+2.4 L
Healthcare Fund	DSP Mutual Fund	7.36 L	106.41	2.77%	0.703%	+2.39 L
Mid Cap FundNEW	Helios Mutual Fund	1.35 L	19.53	0.88%	0.129%	—
(LIVE SCHEMES)	ITI Mutual Fund	1.17 L	16.92	1.07%	0.112%	-0
Balanced Hybrid FundNEW	SBI Mutual Fund	1.16 L	16.77	0.92%	0.111%	—
PHARMA FUND	Nippon India Mutual Fund	1.12 L	16.16	0.17%	0.107%	-0
Small Cap FundNEW	Helios Mutual Fund	1.05 L	15.11	0.87%	0.1%	—

1–8 of 33

1 / 5

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

3

Final dividend24 Jul 2026 · ex-date₹7.55
Final dividend3 Sept 2025 · ex-date₹10.7
Dividend dividend21 Jun 2024 · ex-date₹8.75

1

Board meeting to consider results31 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

4 announcementsExport CSV

28 Sept 2026, 7:02 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

19 Sept 2026, 1:54 pmBoard Meeting

Board Meeting Intimation for Meeting To Be Held On Wednesday, September 23, 2026, Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015 Inter-Alia To Consider The Proposal For Declaration Of Bonus Equity Shares To The Existing Equity Shareholders Of The Company

Exchange filing PDF

18 Sept 2026, 10:22 amCompany Update

Intimation Of Outcome Of U.S. Food And Drug Administration (USFDA) Inspection At Unit II - Valthera Formulation Facility Of The Company

General PDF

17 Sept 2026, 11:08 amCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

Date	Category	Subject	Filing
28 Sept 2026, 7:02 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
19 Sept 2026, 1:54 pm	Board Meeting	Board Meeting Intimation for Meeting To Be Held On Wednesday, September 23, 2026, Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015 Inter-Alia To Consider The Proposal For Declaration Of Bonus Equity Shares To The Existing Equity Shareholders Of The Company

Loading announcements…

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	78.9%	77.5%	74.5%	76.7%
EBITDA margin %	40.2%	42.4%	42.2%	34.8%
EBIT margin %	33.9%	37.2%	37.7%	27.8%
PAT margin %	28.1%	30.3%	31%	24.6%
Working capital
Receivable days	—	125	159	159
Inventory days	—	331	286	485
Payable days	—	150	135	151
NWC days	—	306	310	493
Leverage
Current ratio	—	6.3	6.17	7.39
Debt to EBITDA	—	0.01	0	0
Debt to equity	—	0	0	0
Interest coverage	72	161.5	936.6	1,233.2
Asset turnover	—	0.6	0.59	0.47
Return ratios
Return on assets %	—	18.1%	18.3%	11.6%
Return on capital employed %	—	26.4%	29.1%	17.6%
Return on equity %	—	20.2%	20.5%	12.9%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Concord Biotech Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Dividends3

Board meetings1

Announcements

Ratio timeline

Dividends3

Board meetings1

Not in the F&O segment

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

1

3

1